Buchholz, Anna
Vattai, Aurelia
Fürst, Sophie
Vilsmaier, Theresa
Zati Zehni, Alaleh
Steger, Alexander
Kuhn, Christina
Schmoeckel, Elisa
Dannecker, Christian
Mahner, Sven
Jeschke, Udo
Heidegger, Helene H.
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 19 September 2022
Accepted: 15 November 2022
First Online: 27 November 2022
Declarations
:
: SM reports research funding, advisory board participation, and honorary or travel expenses from AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Hubro, Medac, MSD, Novartis, Nykode, Olympus, PharmaMar, Pfizer, Roche, Sensor Kinesis, Teva, and Tesaro outside the submitted study. CD reports speaker fees from and participation in advisory boards at MSD, GSK, Tesaro, Clovis Oncology, and Roche outside the submitted study. All other authors declare no conflict of interest.
: This study is in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Patient data were anonymized. The study was approved by the ethics committee of the Ludwig-Maximilian-University Munich (reference number 19–261). During experimental and statistical analyses, the authors were blinded for clinicopathological parameters and survival data. The cancer tissue was no longer needed for clinical tests as histopathological diagnostics after surgery had been completed prior to this study.
: When the current study was performed, all diagnostic procedures were completed, and the patients’ data were anonymized. The ethical principles adopted in the Declaration of Helsinki 1975 have been respected. As per the declaration of our ethics committee, no written informed consent of the participants or permission to publish is needed given the circumstances described above. Researchers were blinded from patient data during experimental and statistical analysis.